Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.15% is 33% above its 5-year average of -46.24%, near the high end of its 5-year range (-85.81%–-20.25%).
59.86% above its 12-month average of -77.61%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.68%.
RETURN ON ASSETS (ROA)
-31.15%
RETURN ON ASSETS (ROA) AVG TTM
-77.61%
RETURN ON ASSETS (ROA) AVG 3Y
-57.20%
RETURN ON ASSETS (ROA) AVG 5Y
-46.24%
RETURN ON ASSETS (ROA) AVG 10Y
-41.21%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.86%
CURRENT VS 3Y AVG
+45.54%
CURRENT VS 5Y AVG
+32.63%
CURRENT VS 10Y AVG
+24.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
+1.03%
vs the sector median at left
Editas Medicine, Inc.
Market Cap
$434.82M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$435.48M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
Market Cap
$440.53M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$427.95M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$444.52M
Return on Assets (ROA)
-19.71%
TTM Avg
-24.50%
3Y Avg
-30.22%
5Y Avg
-31.88%
Market Cap
$447.00M
Return on Assets (ROA)
-14.87%
TTM Avg
-20.11%
3Y Avg
-27.86%
5Y Avg
-25.84%
Market Cap
$422.13M
Return on Assets (ROA)
-86.35%
TTM Avg
-25.00%
3Y Avg
-21.41%
5Y Avg
-20.43%
Market Cap
$448.85M
Return on Assets (ROA)
-83.42%
TTM Avg
-53.06%
3Y Avg
-45.42%
5Y Avg
-42.54%
Market Cap
$419.62M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $434.82M | -31.15% | -77.61% | -57.20% | -46.24% |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.48M | -0.01% | -18.05% | -43.07% | -43.70% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.53M | -35.10% | -26.63% | -37.28% | -39.51% |
| NeoGenomics, Inc. (NEO)vs › | $427.95M | -3.84% | -6.38% | -6.57% | -4.38% |
| NeuroPace, Inc. (NPCE)vs › | $444.52M | -19.71% | -24.50% | -30.22% | -31.88% |
| Ovid Therapeutics Inc. (OVID)vs › | $447.00M | -14.87% | -20.11% | -27.86% | -25.84% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.13M | -86.35% | -25.00% | -21.41% | -20.43% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.85M | -83.42% | -53.06% | -45.42% | -42.54% |
| Senseonics Holdings, Inc. (SENS)vs › | $419.62M | -61.86% | -66.50% | -24.17% | -122.74% |
| Rezolute, Inc. (RZLT)vs › | $418.02M | -68.75% | -55.58% | -51.15% | -46.76% |
ROA
-31.1%
ROE
-70.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -85.81% |
| 2024-12-31 | -69.41% |
| 2023-12-31 | -30.70% |
| 2022-12-31 | -42.86% |
| 2021-12-31 | -28.41% |
| 2020-12-31 | -20.25% |
| 2019-12-31 | -26.28% |
| 2018-12-31 | -26.16% |
| 2017-12-31 | -32.24% |
| 2016-12-31 | -42.40% |
| 2015-12-31 | -48.81% |
| 2014-12-31 | -112.28% |
| 2013-12-31 | -215.60% |
